V

Vir Biotechnology

D
VIR
USD
-0.385
(-3.7894%)
Market Closed
27,282.00
Volume
-3.05
EPS
-
Div Yield
-2.748603
P/E
1,335,651,806.53
Market Cap
Today
-0.0511%
1 Week
30.247%
1 Month
32.095%
6 Months
-1.561%
12 Months
15.818%
Year To Date
-2.736%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
MRNA
MRNA
-0.985
(-1.921%)
USD
N
NVAX
0.505
(5.8247%)
USD
GSK
GSK
0.76
(2.117%)
USD
B
BNTX
0.99
(0.9269%)
USD
S
SPCE
-0.855
(-11.9916%)
USD
BA
BA
3.81
(2.589%)
USD
D
DAL
-1.845
(-2.9622%)
USD
U
UAL
0.02
(0.0234%)
USD
A
AAL
-0.38
(-2.7153%)
USD
C
CCL
-0.215
(-0.8992%)
USD
N
NCLH
-0.7
(-2.5221%)
USD

Title:
Vir Biotechnology

Sector:
Healthcare
Industry:
Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development,collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Do you need help or have a question?
Contact Us